Molecular markers in subclinical acute rejection of renal transplants

Clinical Transplantation

Volumn 18, Issue 3, 2004, Pages 281-287

  Aquino Dias, Esther Cristina ^a   Veríssimo Veronese, Francisco José ^a   Santos Gonçalves, Luiz Felipe ^a   Manfro, Roberto Ceratti ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Fas ligand; Granzyme B; Perforin; Renal transplantation; Subclinical rejection

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; FAS LIGAND; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GRANZYME B; MOLECULAR MARKER; PERFORIN; PREDNISONE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ACUTE DISEASE; BIOPSY; GENETIC MARKERS; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION;

EID: 2942515235     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00161.x     Document Type: Article

References (26)

1. Serón D, Díaz-Gallo C, Griñó JM et al. Characterization of interstitial infiltrate in early renal allograft biopsies in patients with stable renal function. Transplant Proc 1991: 23: 1267.
2. Rush DN, Jeffrey J, Gough J. Sequential protocol biopsies in renal transplant patients, Clinical-pathological correlations using the Banff schema. Transplantation 1995: 59: 511.
3. Rush DN, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998: 9: 2129.
4. Rush DN, Karpinski ME, Nickerson P et al. Does subclinical rejection contribute to chronic rejection in renal transplant patients? Clin Transplant 1999: 13: 441.
5. Nickerson P, Jeffrey J, Gough J et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. J Am Soc Nephrol 1999: 10: 1801.
6. Solez K, Axelsen RA, Benediktson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
7. Strehlau J, Pavlakis M, Lipman et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A 1997: 94: 695.
8. Lipman ML, Shen Y, Jeffrey JR et al. Immune-activation gene expression in clinically stable renal allograft biopsies: molecular evidence for subclinical rejection. Transplantation 1998: 66: 1673.
9. Pavlakis M, Lipman M, Strom TB. Intragraft expression of T-cell activation genes in human renal allograft rejection. Kidney Int 1996: 53(Suppl.1): 7.
10. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
11. Rush DN, Henry SF, Jeffrey JR et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994: 57: 208.
12. Legendre C, Thervet E, Skhiri H et al. Histological features of chronic allograft nephropaty revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998: 65: 1506.
13. Veronese FV, Gonçalves LF, Edelweiss MI, Manfro RC. Interpretation of surveillance kidney allograft biopsies according to the Banff criteria. Transplant Proc 1999: 31: 3019.
14. Rush DN, Jeffrey JR, Gough J. Sequential protocol biopsies in renal transplant patients: repeated inflammation is associated with impaired graft function at 1 year. Transplant Proc 1995: 27: 1017.
15. Séron D, Moresco F, Bover J et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997: 51: 310.
16. McWhinnie DL, Thompson JF, Taylor HM et al. Morphometric analysis of cellular infiltration assessed by monoclonal antibody labeling in sequential human renal allograft biopsies. Transplantation 1986: 42: 352.
17. Rush, DN, Nickerson P, Jeffrey JR et al. Protocol biopsies in renal transplantation: research tool or clinically useful? Curr Opin Nephrol Hypertens 1998: 7: 691.
18. Saad R, Gritsch HA, Shapiro R et al. Clinical significance of renal allograft biopsies with 'borderline changes', as defined in the Banff schema. Transplantation 1997: 64: 992.
19. Lipman ML, Stevens AC, Strom TB. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol 1994: 152: 5120.
20. Grimm PC, McKenna R, Nickerson P et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol 1999: 10: 1582.
21. Sharma VK, Bologa RM, Li B et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996: 62: 1860.
22. Vasconcellos LM, Schachter AD, Zheng XX et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998: 66: 562.
23. Li B, Hartono C, Ding R, Sharma VK et al. Noninvasive diagnosis of renal allograft rejection by measurement of messenger RNA for perform and granzyme B in urine. N Eng J Med 2001: 344: 947.
24. Netto MPV, Fonseca BAL, Dantas M et al. Granzyme B, fas-ligand and perform expression during cellular rejection episodes kidney transplantation: comparison between blood and renal aspirates. Transplant Proc 2002: 34: 476.
25. Zhang Z, Ohkohchi N, Sakurada M et al. Analysis of urinary donor derived DNA in renal transplant recipients with acute rejection. Clin Transplant 2002: 16 (Suppl. 8): 45.
26. Sabek O, Dorak MT, Kotb M et al. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation 2002: 7: 701.